Table 2 Clinical trials of CD47/SIRPα targeted agents in solid tumors
From: Targeting macrophages: a novel treatment strategy in solid tumors
mAbs | Inhibitor type | Conditions | Monotherapy or Combination | Number of patients recruited | Phases stage | Clinical trial NO |
|---|---|---|---|---|---|---|
Hu5F9-G4 (Magrolimab) | Humanized, IgG4 | Solid Tumor | Monotherapy | 88 participants | Phase I | NCT02216409 |
AK117(Ligufalimab) | Humanized, IgG4 | Neoplasms Malignan | Monotherapy | 162 participants | Phase I | NCT04728334 |
| Â | Â | Neoplasms Malignan | Monotherapy | 159 participants | Phase I | NCT04349969 |
| Â | Â | Metastatic and locally advanced TNBC | Combination | 80 participants | Phase II | NCT05227664 |
| Â | Â | Advanced malignant tumors | Combination | 130 participants | Phase I/II | NCT05235542 |
| Â | Â | Advanced malignant tumors | Combination | 114 participants | Phase I/II | NCT05229497 |
| Â | Â | Advanced malignant tumors | Combination | 160 participants | Phase I/II | NCT05214482 |
| Â | Â | Metastatic colorectal cancer | Combination | 114 participants | Phase II | NCT05382442 |
AO-176 | Human, IgG4 | Solid tumor | Combination | 183 participants | Phase I/II | NCT03834948 |
SGN-CD47M | Humanized, IgG4 | Solid tumor | Monotherapy | 16 participants | Phase I | NCT03957096 |
CC-9002 | Humanized, IgG4 | Hematologic neoplasms | Monotherapy, or combination | 60 participants | Phase I | NCT02367196 |